Longtime Zymeworks CEO, co-founder Tehrani hits the exit in favor of serial biotech entrepreneur

Ali Tehrani, Zymeworks CEO

Af­ter a down year, bio­phar­ma writ large is look­ing for a breath of fresh air — and now the winds of change have hit on­col­o­gy bis­pecifics play­er Zymeworks. Ali Tehrani, a co-founder of Zymeworks who has been the biotech’s CEO since 2003, has re­signed from his po­si­tion and will be re­placed by Ken Gal­braith, a se­r­i­al biotech en­tre­pre­neur and for­mer board mem­ber, the com­pa­ny said Wednes­day.

Tehrani will take on an ad­vi­so­ry role with the com­pa­ny once his tenure for­mal­ly ends Feb. 1 to help aid in the tran­si­tion for Gal­braith’s lead­er­ship turn. Mean­while, board chair Lota Zoth will be moved in­to an in­de­pen­dent di­rec­tor role in con­junc­tion with the shake­up.

Shares in $ZYME were trad­ing down around 7% on the news ear­ly Thurs­day.

In both a press re­lease and con­cur­rent SEC fil­ing, Zymeworks re­leased no fur­ther de­tails on the rea­sons for Tehrani’s de­par­ture. He and his com­pa­ny came to terms on a sev­er­ance deal that will in­clude a $889,683 lump sum pay­ment as well as a re­main­ing an­nu­al bonus and ben­e­fits. His ad­vi­so­ry con­tract is set to end in Sep­tem­ber 2023. Mean­while, Gal­braith will take the reins at a biotech that has been gung-ho in its ef­forts to rein in a suite of Big Phar­ma part­ners and re­cent­ly flashed some promis­ing da­ta for its bis­pe­cif­ic HER2-tar­get­ed an­ti­body, dubbed zanidatam­ab, at this year’s ES­MO.

Gal­braith has float­ed in and out of biotech lead­er­ship roles for years, most re­cent­ly serv­ing as ex­ec­u­tive-in-res­i­dence at Syn­cona since April and as a man­ag­ing part­ner at Five Cor­ners Cap­i­tal, which he co­found­ed back in 2013. Oth­er stops on his lengthy ré­sumé in­clude CEO of Lim­i­nal Bio­Sciences be­tween April 2019 and No­vem­ber 2020, CEO of Fairhaven Phar­ma­ceu­ti­cals from June 2017 to April 2019, and even as a Zymeworks board mem­ber from 2009 to 2013.

Gal­braith had this to say about his ap­point­ment:

I have long be­lieved in the po­ten­tial of in­no­v­a­tive tech­nol­o­gy plat­forms to gen­er­ate nov­el mul­ti­spe­cif­ic an­ti­bod­ies and an­ti­body-drug con­ju­gates and trans­form the treat­ment of can­cer. Zymeworks’ in­no­v­a­tive ap­proach, tech­nol­o­gy plat­forms and emerg­ing prod­uct pipeline rep­re­sent a tremen­dous op­por­tu­ni­ty, and I look for­ward to lead­ing the Com­pa­ny dur­ing this ex­cit­ing pe­ri­od of in­no­va­tion in can­cer ther­a­pies. This year, we ex­pect to progress our two on­go­ing piv­otal clin­i­cal stud­ies for zanidatam­ab, present im­por­tant new da­ta for zanidatam­ab and ZW49 to in­form ad­di­tion­al clin­i­cal de­vel­op­ment op­por­tu­ni­ties, fur­ther ad­vance our pre­clin­i­cal prod­uct pipeline and gain in­sights from our phar­ma­ceu­ti­cal part­ners’ pro­grams as they ad­vance in­to and through clin­i­cal de­vel­op­ment.

Gal­braith will be due a $600,000 an­nu­al salary plus stocks and op­tions, with the op­tion for an an­nu­al bonus worth up to 60% of that salary fig­ure.

Their Staying Power Lies in their Patient-Centricity

Decentralized clinical trials (DCTs) were traditionally utilized in an isolated fashion prior to the COVID-19 pandemic. To continue their research within the constraints of the pandemic, sponsors and clinical investigators pivoted to a decentralized model out of necessity. At the onset, regulatory agencies offered some guidance on the digital approaches that are acceptable to ensure DCT approaches are applied in a way that maintains patient safety, as well as data quality and integrity.

Patrick Collison, co-founder of Stripe, has become one of Silicon Valley’s biggest advocates for new forms of funding and conducting science (Matt Winkelmeyer/Getty Images for WIRED)

It’s big days for biology.

The pandemic has seen a series of very public scientific breakthroughs: mRNA vaccine, Covid antibodies, CRISPR as therapy. The minds behind these advancements have graced magazine covers and received prestigious awards.

But the last two years have also, far more quietly, seen a series of new experiments in how to fund the next generation of scientific breakthroughs.

Since March 2020, investors, academics, a significant number of Silicon Valley types, at least one Russian billionaire and two crypto billionaires and, most recently, a few West Coast universities have launched a series of grant programs, institutes, NGOs and companies hoping to change how life science research is done. Though unaffiliated and varying greatly in both size and form, they have broadly promised to evade bureaucracy and misaligned incentives and advance both basic and not-so-basic research in ways they say can’t be done in either conventional academia or profit-focused biotech.

Unlock this story instantly and join 127,400+ biopharma pros reading Endpoints daily — and it’s free.

As the FDA is looking to reduce drug shortages further by collecting more data on the volume of drugs and APIs manufactured worldwide, companies like Pfizer, Thermo Fisher, Viatris and industry groups are pushing back on new guidance that seeks to establish how that data should be collected and submitted to the agency.

The technical conformance guide, released last October, spells out the requirements under Section 3112(e) of the CARES Act, which was signed into law in March 2020 and added a new section to the FD&C Act.

Belén Garijo, Merck KGaA CEO (Kevin Wolf/AP Images for EMD Serono)

Bursting at the seams and executing plans for swift expansion to support its manufacturing work for the mRNA vaccine out of Pfizer/BioNTech, Indianapolis-based Exelead has now been scooped up in a $780 million cash buyout deal.

Germany’s Merck KGaA, which bought out another mRNA manufacturer, AmpTec, early last year, has been beefing up its ops around lipids, which, in mRNA vaccines, play a key role in turning human cells into a mini—vaccine factories?

Unlock this story instantly and join 127,400+ biopharma pros reading Endpoints daily — and it’s free.

Jay Bradner, NIBR president (Jeff Rumans)

Alnylam was a few years ahead in the small interfering RNA (siRNA) space when Novartis jumped on the bandwagon in early 2020, licensing the company’s cholesterol-lowering drug Leqvio through its buyout of The Medicines Company. Less than a month after securing an approval, the pharma giant wants more where that came from.

Novartis is joining forces with Alnylam once again for the discovery and development of a regenerative siRNA-based therapy to treat end-stage liver disease, the companies announced on Thursday.

Unlock this story instantly and join 127,400+ biopharma pros reading Endpoints daily — and it’s free.

Sosei Heptares is teaming up with a big-name partner: Alphabet’s Verily.

No financials were disclosed, but the pair will aim to use Verily’s immune profiling and Sosei Heptares’ GPCR drug design capabilities to develop a variety of new therapeutics. The collaboration will focus on GPCR drugs in the immunology, gastroenterology and immuno-oncology spaces, as well as other disorders with immunoprotective or immunopathogenic mechanisms, the companies said.

After showcasing clinical data at #ASH21 for a sickle cell disease candidate, Sanofi has decided to throw in the towel on its 8-year partnership with collaborator Sangamo — and return its rights to the candidate.

The gene editing biotech announced the ‘transition’ this morning, several days after Sanofi told Sangamo that the biotech was backing out of the deal. The Paris-based pharma giant will be returning its rights and obligations on SAR445136, a zinc finger nuclease gene-edited cell therapy back to Sangamo by the end of June.

Chris Perkin, Altasciences via Youtube

Altasciences CEO Chris Perkin has gone through several acquisitions in his 45-year career. And if there’s one thing he learned, it’s how not to go through an acquisition.

His company put that knowledge to use on Tuesday when it announced that it had acquired competitor Sinclair research, a preclinical contract research organization in Missouri. With the pickup, Altasciences gains 80 animal rooms, and full-service IND and NDA-enabling toxicology and safety pharmacology services.

John Maraganore (Scott Eisen/Bloomberg via Getty Images)

On his way out of Alnylam, outgoing CEO John Maraganore, who had led the biotech through thick and thin for 19 years, said late last year he wanted to advise new biotech companies in the grandfather phase of his career.

‘It’s like a grandfather, right? You get the benefit of loving your grandchildren, but not having to take care of them all the time,’ Maraganore said at the time. ‘I want to be a granddad.’
https://endpts.com/longtime-zymeworks-ceo-co-founder-tehrani-hits-the-exit-in-favor-of-serial-biotech-entrepreneur/